TY - JOUR
T1 - Comparison of left bundle branch area pacing and biventricular pacing for atrioventricular block with heart failure and mild-to-moderately reduced left ventricular systolic function
T2 - design and rationale of the BLOCK NAGOYA randomized clinical trial
AU - BLOCK NAGOYA study investigators
AU - Kato, Hiroyuki
AU - Yanagisawa, Satoshi
AU - Morishima, Itsuro
AU - Kanzaki, Yasunori
AU - Suzuki, Hirohiko
AU - Takasugi, Nobuhiro
AU - Sato, Koyo
AU - Warita, Shunichiro
AU - Naruse, Yoshihisa
AU - Yokoi, Kenichiro
AU - Ishikawa, Shinji
AU - Sugiura, Shinya
AU - Mizutani, Yoshiaki
AU - Kamikubo, Yosuke
AU - Goto, Takayuki
AU - Murase, Yosuke
AU - Sakamoto, Yusuke
AU - Yoshimoto, Daisuke
AU - Funabiki, Junya
AU - Kuwatsuka, Yachiyo
AU - Ando, Masahiko
AU - Okumura, Takahiro
AU - Inden, Yasuya
AU - Murohara, Toyoaki
AU - Tsuj, Yukiomi
AU - Shimojo, Masafumi
AU - Sakamoto, Yuichiro
AU - Naganawa, Hirokazu
AU - Yamaguchi, Ryo
AU - Uemura, Yuko
AU - Takemoto, Yoshio
AU - Makino, Yuichiro
AU - Ogura, Yasuhiro
AU - Ando, Monami
AU - Watanabe, Ryo
AU - Oshima, Yoshitake
AU - Sano, Makoto
AU - Narumi, Taro
AU - Kaneko, Yutaro
AU - Ito, Tadahiro
AU - Furui, Koichi
AU - Okajima, Takashi
AU - Imai, Hajime
AU - Mamiya, Keita
AU - Suga, Kazumasa
AU - Ota, Ryusuke
AU - Sakurai, Taku
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2026.
PY - 2026/3
Y1 - 2026/3
N2 - Background: Cardiac resynchronization therapy (CRT) with biventricular pacing (BVP) is an established cardiac physiologic pacing strategy for patients requiring substantial ventricular pacing, heart failure (HF), and reduced left ventricular ejection fraction (LVEF). Recently, left bundle branch area pacing (LBBAP) has emerged as a promising alternative to BVP. It remains uncertain whether BVP or LBBAP is more advantageous for patients with mild-to-moderately reduced left ventricular systolic function. Objective: To compare efficacy and safety of LBBAP and BVP in patients with atrioventricular block and LVEF of 36-50%. Methods: The BLOCK NAGOYA trial is a multicenter, prospective, randomized, controlled trial to determine whether LBBAP is superior to BVP in terms in improving left ventricular function. A total of 46 participants, with advanced atrioventricular block, HF, and LVEF of 36-50%, will be recruited in 17 Japanese institutions and randomized to receive either LBBAP (with targeted left bundle branch capture) or BVP treatment arm. Results: The primary endpoint is the change in LVEF at 6 months. Secondary endpoints include changes in brain natriuretic peptide levels, electrocardiographic and echocardiographic findings at 6 months, clinical outcomes (hospitalization for HF or ventricular arrhythmias), and adverse events. The follow-up duration is set to two years after the implantation. Conclusion: The BLOCK NAGOYA trial will provide significant insights on the optimal physiologic pacing therapy for patients with atrioventricular block, HF, and mild-to-moderately reduced LVEF. Trial registration number: Japan Registry of Clinical Trials: jRCTs042240129: https://jrct.mhlw.go.jp/en-latest-detail/jRCTs042240129
AB - Background: Cardiac resynchronization therapy (CRT) with biventricular pacing (BVP) is an established cardiac physiologic pacing strategy for patients requiring substantial ventricular pacing, heart failure (HF), and reduced left ventricular ejection fraction (LVEF). Recently, left bundle branch area pacing (LBBAP) has emerged as a promising alternative to BVP. It remains uncertain whether BVP or LBBAP is more advantageous for patients with mild-to-moderately reduced left ventricular systolic function. Objective: To compare efficacy and safety of LBBAP and BVP in patients with atrioventricular block and LVEF of 36-50%. Methods: The BLOCK NAGOYA trial is a multicenter, prospective, randomized, controlled trial to determine whether LBBAP is superior to BVP in terms in improving left ventricular function. A total of 46 participants, with advanced atrioventricular block, HF, and LVEF of 36-50%, will be recruited in 17 Japanese institutions and randomized to receive either LBBAP (with targeted left bundle branch capture) or BVP treatment arm. Results: The primary endpoint is the change in LVEF at 6 months. Secondary endpoints include changes in brain natriuretic peptide levels, electrocardiographic and echocardiographic findings at 6 months, clinical outcomes (hospitalization for HF or ventricular arrhythmias), and adverse events. The follow-up duration is set to two years after the implantation. Conclusion: The BLOCK NAGOYA trial will provide significant insights on the optimal physiologic pacing therapy for patients with atrioventricular block, HF, and mild-to-moderately reduced LVEF. Trial registration number: Japan Registry of Clinical Trials: jRCTs042240129: https://jrct.mhlw.go.jp/en-latest-detail/jRCTs042240129
KW - Atrioventricular block
KW - Cardiac resynchronization therapy
KW - Conduction system pacing
KW - Left bundle branch pacing
KW - Left ventricular septal pacing
KW - Pacemaker
UR - https://www.scopus.com/pages/publications/105027763176
UR - https://www.scopus.com/pages/publications/105027763176#tab=citedBy
U2 - 10.1007/s10840-025-02210-9
DO - 10.1007/s10840-025-02210-9
M3 - Article
C2 - 41483053
AN - SCOPUS:105027763176
SN - 1383-875X
VL - 69
SP - 297
EP - 307
JO - Journal of Interventional Cardiac Electrophysiology
JF - Journal of Interventional Cardiac Electrophysiology
IS - 2
ER -